Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Safety and efficacy of statins

The concerns of Rory Collins and colleagues in their recent comprehensive Review1 addressing possible under use of statins, are well received. However, more than half of patients discontinue statin therapy.2 Adverse effects seem likely to contribute to this. The clinical trials discussed by Collins and colleagues were industry-sponsored and designed to show efficacy, not safety. These trials did not recruit patients who were previously intolerant of statins or who had complex comorbidities, making it inevitable that adverse effects were substantially under-represented.

email